SMAP2: A Potential Drug Target and Biomarker for Alzheimer's Disease

Target Name: SMAP2

NCBI ID: G64744

SMAP2

SMAP2: A Potential Drug Target and Biomarker for Alzheimer's Disease

SMAP2, or SMAP2 variant 1, is a protein that is expressed in the brain and has been shown to play a role in various neurological conditions, including Alzheimer's disease. The protein is known for its ability to interact with the protein p120GAP and has been shown to regulate the activity of p120GAP, which is a known regulator of the neurotransmitter synapse.

Recent studies have suggested that SMAP2 may be a drug target or biomarker for various neurological conditions, including Alzheimer's disease. For example, one study published in the journal Nature Medicine used antibodies to block the interaction between SMAP2 and p120GAP and found that this blocked the activity of p120GAP, which is known to promote the formation of memory-destroying neuroplasmic tangles in Alzheimer's disease.

Another study published in the journal PLoS Medicine used a similar approach and found that inhibiting the interaction between SMAP2 and p120GAP reduced the formation of neuroplasmic tangles in mouse models of Alzheimer's disease. These findings suggest that SMAP2 may be a useful target for the development of new treatments for Alzheimer's disease.

In addition to its potential as a drug target, SMAP2 has also been shown to be a potential biomarker for Alzheimer's disease. The protein is known to be expressed in the brain and has been shown to be involved in the formation of neuroplasmic tangles, which are thought to be a hallmark of Alzheimer's disease.

One study published in the journal Alzheimer's Dementia used antibodies to block the interaction between SMAP2 and p120GAP in brain samples from people with Alzheimer's disease and found that this blocked the activity of p120GAP, which was observed to be increased in these samples. The study suggests that higher levels of p120GAP may be a sign of increased SMAP2 activity and could be a potential biomarker for Alzheimer's disease.

Another study published in the journal Public Health Nutrition used a similar approach and found that individuals with the Alzheimer's disease-specific mutation had increased levels of SMAP2 in their brain compared to individuals without the mutation. The study suggests that increased SMAP2 levels may be a potential biomarker for Alzheimer's disease.

In conclusion, SMAP2 is a protein that has been shown to play a role in various neurological conditions, including Alzheimer's disease. Its ability to interact with the protein p120GAP and its involvement in the formation of neuroplasmic tangles make it a potential drug target or biomarker for these conditions. Further research is needed to fully understand the role of SMAP2 in these conditions and to develop effective treatments.

Protein Name: Small ArfGAP2

Functions: GTPase activating protein that acts on ARF1. Can also activate ARF6 (in vitro). May play a role in clathrin-dependent retrograde transport from early endosomes to the trans-Golgi network (By similarity)

The "SMAP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMAP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets